QGEN vs BIO
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 23, 2026
QGEN
BIO
Investment Advisor Scores
BIO
AI Analyst Insights
Detailed Metrics Comparison
| Metric | QGEN | BIO | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 13.3156 | 39.8406 | QGEN |
| PEG Ratio | 1.0647 | 1.1905 | QGEN |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 0.3% | -0.1% | QGEN |
| Earnings Growth | 13.6% | 18.7% | BIO |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 44.9/100 | 37.1/100 | QGEN |
| Profit Margin | 19.5% | 8.6% | QGEN |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | EXTENDED | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
QGEN
MarkupPrice above SMA50, rising 50-day trend (7.5% over 20 days), RSI 61
BIO
MarkupPrice above SMA50, rising 50-day trend (7.9% over 20 days), RSI 78
Fundamentals Snapshot
| Metric | QGEN | BIO |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 17.2 | 37.9 |
| Trailing P/E | 21.5 | 44.4 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.0% |
| Gross Margin | 0.7% | 0.5% |
| Operating Margin | 0.3% | 0.1% |
| EPS | 2.07 | 8.47 |
| Dividend Yield | 0.01% | — |